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Barbara BurtnessThe study of head and neck cancers in the clinic and in
the laboratory has been radically transformed in recent
years. The emergence of a subset of patients with Hu-
man Papillomavirus (HPV)-initiated oropharynx cancer,
now representing the majority of new head and neck
cancers at some sites in the United States, was followed
by the recognition that these HPV-associated cancers
represented a different disease [1]. HPV-initiated cancer
not only has a different etiology, but also differs in treat-
ment responsiveness, and biomolecular profile. Research
on these more curable cancers increasingly will incorp-
orate patient-reported outcomes and survivorship ques-
tions. At the same time, it has become clear that
treatment advances have been only modest for HPV-
negative cancers, and novel approaches to characterizing
tumors and identifying therapeutic targets are urgently
needed for these patients [2].
The advent of next-generation sequencing and pub-
lication of The Cancer Genome Atlas genomic profile
in head and neck cancer have led to an initial classifi-
cation of head and neck cancers into 4 intrinsic sub-
types, with mutations in tumor suppressor genes the
most common molecular abnormalities [3]. Ongoing
efforts are likely to expand on these initial data with
greater numbers of HPV-initiated cancers and cancers
from non-smokers, as well as more detailed integrative
analysis incorporating methylation and proteomic sig-
natures. Successful targeted therapy of cancers driven
by loss of tumor suppressor gene function is likely to
require informatics approaches to identify potential
synthetic lethal targets. The revolution in immuno-
oncology is also relevant in head and neck cancer, with
preliminary data indicating responsiveness to immune
checkpoint inhibition for both HPV-associated and
HPV-negative cancers [4].
The rapidity with which the field is moving, and the rich-
ness of these data sets, creates the need for a new journalCorrespondence: barbara.burtness@yale.edu
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Editorial Board, the ability to rapidly review submissions,
and open access. We intend to publish original articles,
reviews, case reports, and position papers across all disci-
plines that impact the direction of research and clinical
care in head and neck cancer. Studies of standard and
novel treatment approaches, including radiation, surgery,
cytotoxic and targeted systemic therapy, vaccines and im-
munotherapy; translational science characterizing the biol-
ogy of head and neck cancer subtypes, validation of
prognostic and predictive biomarkers, and identification of
novel therapeutics targets; virology of HPV and – for
Epstein-Barr Virus (EBV)-associated nasopharynx cancer –
EBV in the context of the head and neck; prevention strat-
egies for those at risk for head and neck cancer; database
analyses; and strategies to assess and improve functional
outcome and quality of life, will be the core material pub-
lished in Cancers of the Head & Neck.
An Editorial Board has been assembled consisting of
21 distinguished members from Europe, Asia and North
America. Their expertise spans medical oncology, radi-
ation oncology, head and neck surgery, head and neck
pathology, virology, signaling, genomics, biomarkers,
immuno-oncology, and survivorship.
The journal is published by BioMed Central
(BMC)—an important leader in open access publishing,
which currently publishes over 290 peer-reviewed open
access journals. The strength of the BMC editorial of-
fices will support our efforts to publish the highest
quality papers after efficient and fair scientific peer
review. Cancers of the Head & Neck operates a single-
blind peer-review system aiming to provide authors
with a first decision within 6 weeks and once accepted,
to publish manuscripts online within 2 weeks. All arti-
cles in Cancers of the Head & Neck are freely and uni-
versally accessible online upon publication, so authors’
work is available to readers everywhere irrespective of
the wealth of their institution. This ensures that au-
thors’ work is disseminated to the widest possible audi-
ence and fosters the most active academic exchange [5].istributed under the terms of the Creative Commons Attribution 4.0
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